As a clinical-stage biotechnology firm, NexImmune, Inc. is dedicated to developing potentially curative treatments for individuals battling cancer and severe immune disorders. Their approach leverages T cell immunotherapies, based on their exclusive Artificial Immune Modulation (AIM) nanoparticle technology platform. The company's pipeline includes NEXI-001, an allogeneic cell therapy currently undergoing Phase I/II clinical trials for acute myeloid leukemia; NEXI-002, an autologous cell therapy also in Phase I/II studies, targeting relapsed or refractory multiple myeloma; and NEXI-003, an early-stage candidate designed to combat HPV-associated malignancies.